Bausch Health Americas, Inc. (F/K/A Valeant Pharmaceuticals International) FDA Inspection Record
Bausch Health Americas, Inc. (F/K/A Valeant Pharmaceuticals International) is an FDA-registered facility (FEI 3009443653) located in Bridgewater, NJ, US. RegDataLab tracks 6 FDA inspections and 2 compliance actions at this facility.
What FDA found at this site
- Latest inspection
- Sep 11, 2024: No Action Indicated (NAI)
- Inspections on record
- 6 (2 OAI, 4 NAI)
- Last OAI inspection
- Jul 28, 2015
- Warning letters
- 2 listed by FDA for this FEI, latest Nov 3, 2016
- Recalls as the recalling firm
- 4, latest Mar 13, 2017
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Sep 11, 2024 | No Action Indicated (NAI) | No citations listed |
| Feb 2, 2018 | No Action Indicated (NAI) | No citations listed |
| May 10, 2017 | No Action Indicated (NAI) | No citations listed |
| Sep 1, 2016 | No Action Indicated (NAI) | Design validation- Lack of or inadequate procedures (21 CFR 820.30(g)) Lack of or inadequate procedures (21 CFR 820.100(a)) Nonconforming product, Lack of or inadequate procedures (21 CFR 820.90(a)) Documentation (21 CFR 820.100(b)) and 1 more |
| Jul 28, 2015 | Official Action Indicated (OAI) | Lack of or inadequate complaint procedures (21 CFR 820.198(a)) Quarantine - actual practice (21 CFR 211.142(a)) Testing of reconstituted drugs (21 CFR 211.166(a)(5)) Labeling: documentation of exam and review (21 CFR 211.184(d)) and 13 more |
| Jun 26, 2014 | Official Action Indicated (OAI) | Procedures not adequately established or maintained (21 CFR 820.40) Training - Lack of or inadequate procedures (21 CFR 820.25(b)) Lack of or inadequate procedures (21 CFR 820.100(a)) Procedures for product review,disposition lack of/inadequate (21 CFR 820.90(b)(1)) and 2 more |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Mar 13, 2017 | Class II | Z-0384-2018 | Small Particle Aerosol Generator Model SPAG-2 6000 Series (SPAG-2). The SPAG-2 medical… SPAG-2 unit nebulizers from Lot J0571670RA were tested at Next Breath for particle sizing under the validated method, NB-TM-261, In November… |
| Jan 29, 2016 | Class II | Z-1699-2016 | Orapharma (Onpharma) Onset Mixing Pen Rx only, Product/Part Number 1054-02.
Manufactured… It has been determined that the Onset Mixing Pen has an optimal use period of 18 months from start of use. However, the current labeling… |
| Sep 21, 2015 | Class II | Z-0674-2016 | Valeant Pharmaceuticals North America, Small Particle Size Aerosol Generator, SPAG-2 6000… The Serial I.D. Label and some information in the Operation Manual for the SPAG 2 6000 series is incorrect or out of date, including… |
| Oct 2, 2014 | Class III | D-0025-2015 | Hydrocortisone Butyrate Cream 0.1%, Net Wt. 15 gm tubes, Rx only, Manufactured for… and 1 more product Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point |
FDA record score
1 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
7 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Class II recall Z-0384-2018, this FEI as the recalling firm | Mar 13, 2017 | 4 x 0.25 | 1 |
| Warning letter on FDA's dashboard, which does not show close-outs | Nov 3, 2016 | 10 years or older, so it adds no points | 0 |
| Class II recall Z-1699-2016, this FEI as the recalling firm | Jan 29, 2016 | 10 years or older, so it adds no points | 0 |
| Class II recall Z-0674-2016, this FEI as the recalling firm | Sep 21, 2015 | 10 years or older, so it adds no points | 0 |
| Inspection classified OAI | Jul 28, 2015 | 10 years or older, so it adds no points | 0 |
| Warning letter on FDA's dashboard, which does not show close-outs | Sep 3, 2014 | 10 years or older, so it adds no points | 0 |
| Inspection classified OAI | Jun 26, 2014 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Inspection citations | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 16, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 16, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 13, 2026 | Newest record Nov 12, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Bausch Health Americas, Inc. (F/K/A Valeant Pharmaceuticals International) as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Bausch Health Americas, Inc. (F/K/A Valeant Pharmaceuticals International) yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Bausch Health Americas, Inc.
- Location
- Bridgewater, NJ (US)
- Source
- device